Nicholas Cost, Lindsay A. Renfro, Matthew R. Zibelman, Ana M. Molina, Mamta Parikh, Luke E. Pater, Ian Tfirn, Elizabeth A. Mullen, Peter F. Ehrlich, Elisabeth T. Tracy, John A. Kalapurakal, Jeffrey Dome, James I. Geller. "AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4521